Marinus Pharmaceuticals price target lowered to $24 from $32 at Baird

Baird analyst Brian Skorney lowered the firm’s price target on Marinus Pharmaceuticals to $24 from $32 and keeps an Outperform rating on the shares. The analyst said earnings broadly met expectations, with the PRV sale and equity offering bolstering the balance sheet as the CDD launch progresses and data catalysts come into view.